Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16424868rdf:typepubmed:Citationlld:pubmed
pubmed-article:16424868lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16424868lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:16424868lifeskim:mentionsumls-concept:C1517806lld:lifeskim
pubmed-article:16424868lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:16424868lifeskim:mentionsumls-concept:C0063217lld:lifeskim
pubmed-article:16424868pubmed:issue3lld:pubmed
pubmed-article:16424868pubmed:dateCreated2006-2-23lld:pubmed
pubmed-article:16424868pubmed:abstractTextThe effects of the hyperforin (HF), a natural phloroglucinol purified from Hypericum perforatum, were investigated ex vivo on leukemic cells from patients with B-cell chronic lymphocytic leukemia (B-CLL). HF was found to promote apoptosis of B-CLL cells, as shown by time- and dose-dependent stimulation of phosphatidylserine externalization and DNA fragmentation, by disruption of the mitochondrial transmembrane potential, caspase-3 activation and cleavage of the caspase substrate PARP-1. Moreover, HF-induced downregulation of Bcl-2 and Mcl-1, two antiapoptotic proteins that control mitochondrial permeability. HF also downregulated two proteins which are overexpressed by B-CLL patients' cells, the cell cycle inhibitor p27kip1 through caspase-dependent cleavage into a p23 form, and the nitric oxid (NO) synthase of type 2 (inducible NO synthase). This latter was accompanied by reduction in the production of NO known to be antiapoptotic in B-CLL cells. Preventing effects of the general caspase inhibitor z-VAD-fmk indicated that HF-promoted apoptosis of B-CLL cells was mostly caspase dependent. Furthermore, normal B lymphocytes purified from healthy donors appeared less sensitive to HF-induced apoptosis than B-CLL cells. These results indicate that HF may be of interest in the development of new therapies for B-CLL based on the induction of apoptosis and combination with cell cycle-dependent antitumor drugs.lld:pubmed
pubmed-article:16424868pubmed:languageenglld:pubmed
pubmed-article:16424868pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:citationSubsetIMlld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16424868pubmed:statusMEDLINElld:pubmed
pubmed-article:16424868pubmed:monthMarlld:pubmed
pubmed-article:16424868pubmed:issn0887-6924lld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:BillardCClld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:FourneronJ...lld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:QuinetFFlld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:FaussatA MAMlld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:SalanoubatCClld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:MATAL JLJlld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:EnsafAAlld:pubmed
pubmed-article:16424868pubmed:authorpubmed-author:Naït-SiYYlld:pubmed
pubmed-article:16424868pubmed:issnTypePrintlld:pubmed
pubmed-article:16424868pubmed:volume20lld:pubmed
pubmed-article:16424868pubmed:ownerNLMlld:pubmed
pubmed-article:16424868pubmed:authorsCompleteYlld:pubmed
pubmed-article:16424868pubmed:pagination491-7lld:pubmed
pubmed-article:16424868pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:meshHeadingpubmed-meshheading:16424868...lld:pubmed
pubmed-article:16424868pubmed:year2006lld:pubmed
pubmed-article:16424868pubmed:articleTitlePro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia.lld:pubmed
pubmed-article:16424868pubmed:affiliationUMR 736 INSERM/Université Paris VI, Centre de Recherches Biomédicales des Cordeliers, Paris, France.lld:pubmed
pubmed-article:16424868pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16424868pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16424868lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16424868lld:pubmed